when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

Oncology · news · pharmadog

← back to Oncology

News · Oncology

910 stories

Jun 5, 26STAT+: Will Makary’s FDA voucher program survive?stat

Jun 5, 26STAT+: Up and down the ladder: The latest comings and goingsstat

Jun 5, 26STAT+: Pharmalittle: We’re reading about Roche accusing U.S. of ‘blackmail,’ a ruling on skinny labels, and morestat

Jun 5, 26Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?biopharma dive

Jun 5, 26Opinion: How living and practicing medicine abroad complicated my beliefs about universal health care systemsstat

Jun 4, 26HHS confirms Americans with high-risk Ebola exposures will have access to experimental therapystat

Jun 4, 26STAT+: Drug companies, patient groups urge FDA to pause commissioner’s voucher programstat

Jun 4, 26What RevMed’s pancreatic cancer drug meant for one patientstat

Jun 4, 26STAT+: Otsuka kidney drug slowed loss of function, but less than expected, in late-stage trialstat

Jun 4, 26STAT+: Supreme Court backs generic drugmaker in ‘skinny labeling’ casestat

Jun 4, 26STAT+: For pancreatic cancer patients, an exciting drug can feel out of reachstat

Jun 4, 26STAT+: AI titans push Congress for DNA safeguardsstat

Jun 4, 26An ADC specialist sinks on safety concerns for blood cancer drugbiopharma dive

Jun 4, 26Otsuka showcases kidney drug data; Pfizer cuts an AI dealbiopharma dive

Jun 4, 26STAT+: Pharmalittle: We’re reading about fewer pharma investments in Germany, growing U.S. layoffs, and morestat

Jun 4, 26Scientists uncover a new hiding spot for HIVstat

Jun 4, 26STAT+: Does Revolution Medicines’ pancreatic cancer drug have even greater potential?stat

Jun 4, 26Male puberty is understudied — but when it starts may predict long-term health risksstat

Jun 4, 26Opinion: Grail’s multi-cancer early detection trial was negative. But as an oncologist, I see more to this storystat

Jun 4, 26Opinion: Lawmakers promised cancer patients would be protected from Medicaid cuts. Now CMS says otherwisestat

Jun 4, 26STAT+: After hospitals, patients get a turn to bring AI into the doctor’s officestat

Jun 4, 26A Spanish biotech banks $87M to make differentiated ADCsbiopharma dive

Jun 3, 26STAT+: Alnylam to partner with Inceptive Nucleics for AI foundation models for RNAi therapeuticsstat

Jun 3, 26Legend surges on early data for ‘in vivo’ lymphoma cell therapybiopharma dive

Jun 3, 26House bill aims to crack down on China biotech dealsbiopharma dive

Jun 3, 26NewLimit’s $435M megaround; Lilly’s busy dealmaking weekbiopharma dive

Jun 3, 26STAT+: Legend Biotech emerged as a rare market winnerstat

Jun 3, 26STAT+: Pharmalittle: We’re reading about GLP-1 drugs and knees, FDA cell and gene therapy guidance, and morestat

Jun 3, 26Opinion: The medical-billing AI arms race between providers and insurancestat

Jun 3, 26STAT+: Trump’s Medicaid work requirements have an unwelcome surprise for some states and patientsstat

← prevpage 19 of 31next →